Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Recurrent Non-small Cell Lung Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Recurrent Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Cediranib
Wake Forest University Health Sciences
Phase 2BBB
Bortezomib
Memorial Sloan Kettering Cancer Center
Phase 2BBB
Inno-206
Tianjin Medical University Cancer Institute and Hospital
Phase 3BBB
Cixutumumab
Eli Lilly and Company
Phase 2BB
PREDNISONE TABLETS
Pfizer
Phase 3BB

View all 23 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Metastases, NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →